将 Venetoclax 单药疗法作为水泡性浆细胞树突状细胞肿瘤的一线疗法。

IF 0.7 Q4 HEMATOLOGY Leukemia Research Reports Pub Date : 2023-07-03 eCollection Date: 2023-01-01 DOI:10.1016/j.lrr.2023.100380

Ankit Mitesh Shah, Denise Pereira, Julio Poveda, Trent Peng Wang

{"title":"将 Venetoclax 单药疗法作为水泡性浆细胞树突状细胞肿瘤的一线疗法。","authors":"Ankit Mitesh Shah, Denise Pereira, Julio Poveda, Trent Peng Wang","doi":"10.1016/j.lrr.2023.100380","DOIUrl":null,"url":null,"abstract":"Venetoclax is an approved treatment for relapsed/refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We report a unique case of venetoclax monotherapy used for front-line induction and as a bridge to allogeneic hematopoietic stem cell transplantation (HCT). Venetoclax therapy resulted in rapid complete resolution of skin lesions, however, treatment interruption due to neutropenia led to brisk cancer recurrence. Fortunately, the patient responded to re-challenge and was able to undergo HCT. Venetoclax is active in the first-line treatment setting for BPDCN, however its effect on blood counts and durability of response should be further studied.","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10719512/pdf/","citationCount":"0","resultStr":"{\"title\":\"Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm.\",\"authors\":\"Ankit Mitesh Shah, Denise Pereira, Julio Poveda, Trent Peng Wang\",\"doi\":\"10.1016/j.lrr.2023.100380\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Venetoclax is an approved treatment for relapsed/refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We report a unique case of venetoclax monotherapy used for front-line induction and as a bridge to allogeneic hematopoietic stem cell transplantation (HCT). Venetoclax therapy resulted in rapid complete resolution of skin lesions, however, treatment interruption due to neutropenia led to brisk cancer recurrence. Fortunately, the patient responded to re-challenge and was able to undergo HCT. Venetoclax is active in the first-line treatment setting for BPDCN, however its effect on blood counts and durability of response should be further studied.\",\"PeriodicalId\":38435,\"journal\":{\"name\":\"Leukemia Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10719512/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.lrr.2023.100380\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.lrr.2023.100380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Venetoclax 是一种已获批准的治疗复发/难治性浆细胞性树突状细胞肿瘤（BPDCN）的药物。我们报告了一例独特的Venetoclax单药治疗病例，该疗法用于一线诱导治疗，并作为异基因造血干细胞移植（HCT）的桥梁。Venetoclax治疗使皮肤病变迅速完全消退，然而，由于中性粒细胞减少症而中断治疗导致癌症迅速复发。幸运的是，患者对再次挑战做出了反应，得以接受 HCT 治疗。Venetoclax在BPDCN的一线治疗中具有积极作用，但其对血细胞计数和反应持久性的影响还需进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm.

Venetoclax is an approved treatment for relapsed/refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We report a unique case of venetoclax monotherapy used for front-line induction and as a bridge to allogeneic hematopoietic stem cell transplantation (HCT). Venetoclax therapy resulted in rapid complete resolution of skin lesions, however, treatment interruption due to neutropenia led to brisk cancer recurrence. Fortunately, the patient responded to re-challenge and was able to undergo HCT. Venetoclax is active in the first-line treatment setting for BPDCN, however its effect on blood counts and durability of response should be further studied.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊